The difference is that in that trial they weren't looking at health outcomes. They were looking at people's blood and measuring antibodies.
If it turns out that 25mg produces a small amount of antibodies - but that small amount is still more than enough to prevent the same number of hospitalizations that 100mg does - then it make sense to go with that.
The dosage trials were only used to study the microbiology. Not the death/hospitalization outcomes.
If it turns out that 25mg produces a small amount of antibodies - but that small amount is still more than enough to prevent the same number of hospitalizations that 100mg does - then it make sense to go with that.
The dosage trials were only used to study the microbiology. Not the death/hospitalization outcomes.